Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.

Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, Sugiyama S, Jinnouchi H, Waki M, Doi N, Horii M, Kawata H, Somekawa S, Soeda T, Uemura S, Saito Y; investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial.

Circ J. 2013;77(12):3023-8. Epub 2013 Sep 13.

2.

Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.

Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Sakuma M, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators.

J Cardiol. 2013 Sep;62(3):165-70. doi: 10.1016/j.jjcc.2013.03.015. Epub 2013 Jun 16.

3.

Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.

Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators.

Diabetes Care. 2011 Feb;34(2):280-5. doi: 10.2337/dc10-1615.

4.

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators.

JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9. Erratum in: JAMA. 2009 May 13;301(18):1882. JAMA. 2012 Nov 14;308(18):1861.

PMID:
18997198
5.

Interleukin-6-producing thymic squamous cell carcinoma associated with Castleman's disease and nephrotic syndrome.

Matsumura N, Shiiki H, Saito N, Uramoto H, Hanatani M, Nonaka H, Nakamura S.

Intern Med. 2002 Oct;41(10):871-4.

6.

Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome.

Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M.

Muscle Nerve. 1998 Nov;21(11):1390-7.

PMID:
9771661
7.

An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.

Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H.

Hybridoma. 1998 Apr;17(2):185-90.

PMID:
9627059
8.

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.

Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T.

J Natl Cancer Inst. 1997 Jan 15;89(2):139-47.

PMID:
8998183
9.

Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated.

Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, Honmura S, Yamashita K.

Diabetes Care. 1996 Nov;19(11):1306-7. No abstract available.

PMID:
8908405
10.

[An autopsy case of systemic lupus erythematosus complicating leukocytosis, amegakaryocytic thrombocytopenia, interstitial pneumonitis, and pleulitis].

Kawamoto A, Shiiki H, Hanatani M, Hashimoto T, Dohi K.

Nihon Rinsho Meneki Gakkai Kaishi. 1996 Jun;19(3):223-31. Japanese.

PMID:
8810548
11.

Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells.

Sone H, Kawakami Y, Okuda Y, Kondo S, Hanatani M, Suzuki H, Yamashita K.

Biochem Biophys Res Commun. 1996 Apr 5;221(1):193-8.

PMID:
8660335
12.

Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture.

Sone H, Okuda Y, Kawakami Y, Kondo S, Hanatani M, Matsuo K, Suzuki H, Yamashita K.

Life Sci. 1996;59(1):21-5.

PMID:
8684267
13.

Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum.

Hanatani M, Tanaka Y, Kondo S, Ohmori I, Suzuki H.

Biosci Biotechnol Biochem. 1995 Oct;59(10):1958-9.

14.

[The clinico-pathological significance of hematuria in diabetics].

Matsumura N, Hanatani M, Nishino T, Ishihara K, Kishimoto T, Tonomura Y, Shiiki H, Kanauchi M, Dohi K.

Nihon Jinzo Gakkai Shi. 1994 Sep;36(9):1036-45. Japanese.

PMID:
7967175
15.

Rapid measurement of urinary IL-6 by ELISA: urinary IL-6 as a marker of mesangial proliferation.

Hirata E, Iwano M, Hirayama T, Horii Y, Kitamura Y, Kishimoto T, Hanatani M, Dohi K.

Nihon Jinzo Gakkai Shi. 1994 Jan;36(1):33-7.

PMID:
8107306
16.

[Decompensated benign nephrosclerosis and focal sclerosing glomerulonephritis. Diagnosis and differential diagnosis].

Hanatani M, Wehrmann M, Bohle A.

Pathologe. 1991 Sep;12(5):233-8. German. No abstract available.

PMID:
1946228
17.

[Membranoproliferative glomerulonephritis in non-Hodgkin's lymphoma nad myeloproliferative syndrome--a causal relationship?].

Gärtner HV, Arck P, Hanatani M, Settgast N, Wanninger R, Lederle RM, Erley C, Mikeler E.

Verh Dtsch Ges Pathol. 1991;75:229-34. German.

PMID:
1724839
18.

Lipid peroxidation in the liver of carcinogen-resistant rats.

Hammad H, Higashi T, Tateishi N, Hanatani M, Sakamoto Y.

Biochim Biophys Acta. 1990 Jul 16;1045(2):99-106.

PMID:
2116179
19.

Focal and segmental glomerulosclerosis in preeclamptic patients with nephrotic syndrome.

Shiiki H, Dohi K, Hanatani M, Fujii Y, Sanai H, Ichijo M, Shimamoto I, Ishikawa H, Watanabe T.

Am J Nephrol. 1990;10(3):205-12.

PMID:
2382682
20.

[Three cases presenting with systemic lupus erythematosus and minimal change nephrotic syndrome].

Matsumura N, Dohi K, Shiiki H, Morita H, Yamada H, Fujimoto J, Kanauchi M, Hanatani M, Ishikawa H.

Nihon Jinzo Gakkai Shi. 1989 Sep;31(9):991-9. Japanese.

PMID:
2585838

Supplemental Content

Loading ...
Support Center